NASDAQ:ACIU AC Immune Q2 2025 Earnings Report $2.07 +0.08 (+4.02%) Closing price 04:00 PM EasternExtended Trading$2.04 -0.03 (-1.69%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast AC Immune EPS ResultsActual EPSN/AConsensus EPS -$0.18Beat/MissN/AOne Year Ago EPSN/AAC Immune Revenue ResultsActual RevenueN/AExpected Revenue$1.98 millionBeat/MissN/AYoY Revenue GrowthN/AAC Immune Announcement DetailsQuarterQ2 2025Date8/5/2025TimeBefore Market OpensConference Call DateFriday, August 1, 2025Conference Call Time12:00AM ETConference Call ResourcesEarnings HistoryCompany Profile AC Immune Earnings HeadlinesACIU AC Immune SA - Seeking AlphaJune 29, 2025 | seekingalpha.comAC Immune SA (ACIU) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cracked the code to mass-produce it — making this wonder-material cheaper, scalable, and ready for industrial use. Stronger than steel, lighter than aluminum, and more conductive than copper… this could transform everything from energy to aerospace.July 8 at 2:00 AM | True Market Insiders (Ad)AC Immune Ltd Analysis & Opinion (ACIU) - Investing.comJune 25, 2025 | investing.comAC Immune SA Announces Board Changes Ahead of June 2025 AGMMay 19, 2025 | tipranks.comAC Immune SA Reports Q1 2025 Financial Results and Clinical Advancements in Neurodegenerative Disease TherapiesMay 1, 2025 | nasdaq.comSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) AG (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on the discovery and development of therapies for Alzheimer’s disease and other neurodegenerative disorders. The company leverages two proprietary technology platforms—Morphomer™ for small-molecule therapies and SupraAntigen™ for antibody and vaccine development—to target misfolded proteins implicated in conditions such as Alzheimer’s, Parkinson’s and Creutzfeldt-Jakob disease. The firm’s pipeline includes multiple clinical-stage assets designed to address both amyloid-beta and tau pathologies. Lead programs include antibody candidates in collaboration with global partners and a proprietary tau vaccine in Phase 2 development. Preclinical efforts extend to novel small molecules aimed at inhibiting toxic protein aggregation, with the goal of modifying disease progression rather than solely treating symptoms. Since its founding in 2003, AC Immune has established collaborations with major biopharma companies to co-develop and commercialize its therapeutic candidates. The company maintains research facilities in Switzerland and the United States, enabling seamless integration of discovery, translational and clinical activities across geographies. Partnerships have provided access to complementary expertise, regulatory support and global development networks. AC Immune is led by a management team of seasoned industry professionals, spearheaded by co-founder and Chief Executive Officer Andrea Pfeifer. The board of directors and scientific advisory panels bring extensive experience in neuroscience, drug development and regulatory affairs. Through its dual‐platform approach, AC Immune aims to deliver novel treatments that can alter the course of devastating neurodegenerative diseases.Written by Jeffrey Neal JohnsonView AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
